21 April, 2025 – Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Jechobio”), in collaboration with Wuhan Raydif Biotechnology Co., Ltd. (hereinafter referred to as “Raydif”), and Grand Pharmaceutical Group Limited (stock code: 00512.HK, hereinafter referred to as “Grand Pharma”), have jointly developed GPN02006, an innovative radionuclide-drug conjugate(RDC) targeting Glypican 3 (GPC3). The clinical results of GPN02006 were recently presented at the 2025 Future XDC New Drug Conference (list city location). Clinical strial data demonstrate that GPN02006 exhibits excellent safety and imaging efficacy, providing a novel solution for precision diagnosis of tumors with high GPC3 expression, such as liver cancer. No drug-related adverse reactions were reported in any of the subjects after administration, showcasing outstanding safety and tolerability; high-quality imaging can be achieved as early as 30 minutes post-dosing, fully meeting the rapid diagnostic needs for hepatocellular carcinoma.
An Innovative Antibody Technology Platform as the Cornerstone of Precision Targeting
The remarkable clinical outcomes of GPN02006 represent a significant breakthrough in the field of radionuclide drugs and highlight the combined core R&D strengths of the three partners. Jechobio, leveraging its proprietary phage antibody library platform, VHH nanobody platform, and single B antibody discovery platform, has established a diverse antibody development system encompassing single-chain antibody fragments (scFv), nanobodies (VHH), Fab, IgG, and other formats. Through these platforms, Jechobio has successfully screened multiple innovative molecules that it is advancing to the clinic.
The GPC3 scFv targeting moiety of GPN02006 developed by Jechobio demonstrates three unique advantages: 1) High specificity and strong affinity -precise recognition of the GPC3 target ensures efficient tumor tissue targeting of the drug; 2) Excellent pharmacokinetic (PK) properties -perfect matching with the imaging agent lays the foundation for radionuclide drug development; 3) Outstanding safety -no adverse reactions were observed in preliminary human trials. These advantages demonstrate Jechobio’s innovative capabilities in the field of antibody drug research and development.
The Powerful Combination of Antibody + Radionuclide Drug”
The success of GPN02006 is a testament to the powerful combination of antibody technology + radionuclide drug development.
To date, this GPC3-targeting RDC clinical trial has enrolled over 80 patients and has demonstrated excellent performance in an investigator-initiated trial (IIT): 1) Exceptional safety: no drug-related adverse events were observed in any subjects; 2) Efficiency and convenience: effective imaging can be achieved 30 minutes post-injection; 3) Superior image quality: low background signal and strong tumor uptake provide a reliable basis for precise diagnosis of liver cancer.
With the rapid development of precision medicine, radionuclide-drug conjugates (RDCs) have emerged as a new frontier in tumor diagnosis and treatment.
About Jechobio
Jecho Biopharmaceuticals Co., Ltd., (Jechobio) is a biotech company jointly established by renowned investment companies and Jecho Laboratories, Inc. (USA). Located in Tianjin Sino-Singapore Eco-City since January 2015, Jechobio specializes in research and development, chemistry, manufacturing and controls (CMC), and clinical development of biological therapeutics. Jechobio’s product pipelines are positioned to address unmet clinical needs, focusing on developing a new generation of globally innovative first-in-class (FIC) and best-in-class (BIC) biotherapeutics. Its product portfolio covers monoclonal antibodies, bispecific antibodies, recombinant proteins, oncolytic viruses, immunotoxins, and antibody-drug conjugates. With more than twenty programs in the pipeline, Jechobio has obtained nearly 10 clinical approvals, including those from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), with the lead product having completed Phase III clinical studies and ready for Biologics License Application (BLA).
About Raydif
Wuhan Raydif Biotechnology Co., Ltd., is a biotech company dedicated to the R&D of innovative radionuclide drugs. Adhering to the principle of “driving radionuclide drug development through technological innovation,” Raydif strives to build an innovative radionuclide drug research and translation platform, focusing on global radionuclide drug frontiers and addressing new needs in precision diagnostics and treatment. Currently, the company has multiple pipelines in the field of tumor diagnostics and treatment and has established project collaborations with several renowned domestic and international pharmaceutical companies.
About Grand Pharma
Grand Pharmaceutical Group Limited is a technology-innovative international pharmaceutical enterprise integrating pharmaceutical technology, radionuclide tumor diagnostics, and precise interventional treatment technology for cardiovascular and cerebrovascular diseases.
To date, Grand Pharma is the largest reserve of RDC innovative drugs in Phase III clinical studies for diagnosis and treatment in China and is also one of the innovative pharmaceutical enterprises worldwide that has the most comprehensive product pipelines and integrated diagnosis and treatment plans in the field of radionuclide drugs for cancer treatment.